Enveric Biosciences, Inc.(ENVB)Earnings, Financials & Key RatiosEnveric Biosciences, Inc. (ENVB) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on dilutive financing to support operations, evidenced by a $4.9 million cash balance against persistent quarterly losses, presents a high risk of further shareholder value erosion.
Enveric Biosciences, Inc. (ENVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Enveric Biosciences, Inc. (ENVB) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.08 | — |
| Q2 2026 | Mar 27, 2026 | $0.85vs $55.80+101.5% | — |
| Q4 2025 | Nov 14, 2025 | $10.81vs $63.00+82.8% | — |
| Q3 2025 | Aug 14, 2025 | $11.64vs $63.00+81.5% | — |
Recent stock market news and headlines for Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics t
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxic.
Key metrics vs top competitors for Enveric Biosciences, Inc. (ENVB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.45 | $865.67K | -0.04 | — | — | -420.48% | — | |
| $12.99 | $1.25B | -4.22 | — | — | -151.02% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $130.60 | $17.89B | 5856.50 | 2.72% | 3.46% | 2.79% | — |
Enveric Biosciences, Inc. (ENVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Enveric Biosciences, Inc. (ENVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 29, 2026·SEC
May 15, 2026·SEC
Apr 30, 2026·SEC
Get notified when ENVB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Enveric Biosciences, Inc. (ENVB) stock FAQ — growth, dividends, profitability & financials explained
Enveric Biosciences, Inc. (ENVB) reported a net loss of $8.2M for fiscal year 2025.
Enveric Biosciences, Inc. (ENVB) has a return on equity (ROE) of -420.5%. Negative ROE indicates the company is unprofitable.
Enveric Biosciences, Inc. (ENVB) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.
